Table 2.

Logistic regression models of STI/HIV services by contraceptive type among sexually active adolescent and young adult women 15–24 years, 2011–2015 National Survey of Family Growth

	Chlamydia testing		Any STI testing		HIV testing		Sexual risk assessment (2013–2015 only)
	PR (95% CI) (n = 2,005)	aPR (95% CI) (n = 1,976)	PR (95% CI) (n = 2,007)	aPR (95% CI) (n = 1,978)	PR (95% CI) (n = 2,017)	aPR (95% CI) (n = 1,988)	PR (95% CI) (n = 971)	aPR (95% CI) (n = 950)
LARC versus moderately effective
Continuing LARC	.91 (.68–1.21)	.88 (.65–1.20)	.91 (.70–1.17)	.84 (.64–1.12)	.60 (.39–.93)	.52 (.32–.85)	.76 (.60–.97)	.78 (.61–1.01)
New LARC	1.10 (.82–1.47)	.98 (.73–1.30)	1.06 (.81–1.39)	.89 (.67–1.20)	1.12 (.69–1.82)	.88 (.50–1.54)	.99 (.79–1.24)	1.01 (.80–1.26)
LARC versus less effective
Continuing LARC	1.16 (.85–1.57)	1.17 (.87–1.59)	1.12 (.85–1.48)	1.11 (.83–1.48)	.86 (.54–1.36)	.84 (.50–1.40)	1.03 (.76–1.40)	1.05 (.78–1.41)
New LARC	1.40 (1.04–1.90)	1.30 (.95–1.79)	1.32 (.99–1.75)	1.18 (.86–1.61)	1.60 (.96–2.64)	1.41 (.81–2.46)	1.34 (1.01–1.78)	1.35 (1.03–1.76)
LARC versus no contraception
Continuing LARC	1.52 (1.09–2.12)	1.52 (1.08–2.15)	1.32 (.99–1.74)	1.29 (.95–1.75)	.78 (.48–1.25)	.77 (.45–1.31)	1.02 (.74–1.41)	1.11 (.80–1.55)
New LARC	1.84 (1.34–2.53)	1.69 (1.24–2.29)	1.54 (1.16–2.06)	1.37 (1.00–1.87)	1.45 (.86–2.43)	1.30 (.73–2.32)	1.32 (1.02–1.72)	1.43 (1.11–1.85)

Adjusted models include age, race/ethnicity, insurance status, mother’s highest level of education, usual source of care, live birth in the past year, number of partners, and data collection period. Bold findings indicate confidence interval does not overlap with 1.

aPR = adjusted prevalence ratio; CI = confidence interval; LARC = long-acting reversible contraception; PR = prevalence ratio.